MichelleElizabethMeliskoMD

Oncology • San Francisco, CA

Breast Cancer, Hematologic Oncology, Hospice & Palliative

Clinical Professor, Medicine, UCSF School of Medicine

Join to view full profile

Dr. Melisko is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Melisko's full profile

Already have an account?

Office
1600 Divisadero St
San Francisco, CA 94143
Phone+1 415-353-7070

Fax+1 415-353-9898

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2000 - 2003
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1997 - 2000
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 1997

Certifications & Licensure

CA State Medical License 1998 - 2026
American Board of Internal Medicine Hospice and Palliative Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com

Clinical Trials

Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases Start of enrollment: 2005 Feb 01
Completed
Phase 2
Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients Start of enrollment: 2007 Mar 01
Completed
Phase 2
Comparing (SIS.NET) to Standard Care in Patients Who Have Completed the Acute Phase of Treatment for Early Breast Cancer Start of enrollment: 2011 Jan 01
Completed
Not Applicable
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Start of enrollment: 2011 Nov 01
Completed
Phase 3
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases Start of enrollment: 2012 Feb 01
Active, not recruiting
Phase 2
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies Start of enrollment: 2012 Mar 27
Completed
Phase 1, Phase 2
Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer Start of enrollment: 2016 Aug 02
Completed
Join now to see all

Publications & Presentations

PubMed

39 citations
The symptom phenotype of oncology outpatients remains relatively stable from prior to through 1 week following chemotherapy.
Christine Miaskowski, Bruce A. Cooper, Bradley E. Aouizerat, Michelle E. Melisko, Lee-may Chen
European Journal of Cancer Care. 2017-05-01
419 citations
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adapt...
Rita Nanda, Minetta C. Liu, Christina Yau, Rebecca Shatsky, Lajos Pusztai
JAMA Oncology. 2020-05-01
151 citations
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Lajos Pusztai, Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du
Cancer Cell. 2021-07-12

Press Mentions

ESMO Breast Cancer Roundtable: Episode 5November 13th, 2019
OncLive® Presents the Latest State of the Science Summit™ on Breast CancerSeptember 25th, 2018
Expert Raises QoL Concerns with Adjuvant Hormonal Therapy in ER+ Breast CancerOctober 31st, 2017
Join now to see all